Conservative management of pituitary tumor apoplexy

Tratamento conservador da apoplexia pituitária

Antonio Benigno A. Santos¹, Mariana M. França¹, Renata M. Hirosawa¹, Mônica Marivo¹, Marco A. Zanini², Vania S. Nunes¹

SUMMARY
Pituitary tumor apoplexy is a rare neuroendocrine syndrome resulting, in most cases, from hemorrhage or infarctation of a pre-existing pituitary adenoma. Treatment recommendations vary; some authors advocate urgent surgical decompression of the tumor, whereas others suggest that conservative management can lead to recovery of neuro-ophthalmologic function. We describe two patients with pituitary tumor apoplexy who had clinically non-functioning macroadenomas and hypopituitarism, including hypogonadism. They were treated conservatively without surgery, and achieved tumor remission. Arq Bras Endocrinol Metab. 2011;55(5):345-8

SUMÁRIO
A apoplexia pituitária é uma rara síndrome neuroendócrina causada, na maioria dos casos, pela hemorragia ou enfarte de um adenoma pituitário preexistente. O tratamento recomendado é variável; alguns autores defendem a descompressão cirúrgica do tumor em regime de urgência, enquanto outros sugerem que o tratamento conservador pode levar à recuperação da função neurooftalmológica. Descrevemos os casos de dois pacientes com apoplexia pituitária que apresentaram macroadenomas clinicamente não secretores e hipopituitarismo, incluindo hipogonadismo. Ambos foram submetidos ao tratamento conservador, sem cirurgia, e houve a remissão do tumor. Arq Bras Endocrinol Metab. 2011;55(5):345-8

INTRODUCTION
Pituitary tumor apoplexy is a rare neuroendocrine syndrome resulting, in most cases, from hemorrhage or infarctation of a pre-existing pituitary adenoma. The diagnosis is based more on clinical findings than on pathological examination, and therefore should only apply to patients with signs and symptoms of meningeal irritation or of compression of structures proximal to the sella turcica (1).

Prevalence of pituitary tumor apoplexy has been hard to determine, principally because it is underdiagnosed. In the majority of the epidemiological surveys, percentage of patients with the condition was calculated from the number of patients treated with surgery. Prevalence varies between 0.6% and 10%, usually < 5%, with a mean of 2% of all surgically resected adenomas (2).

The pathophysiological mechanism involved in the genesis of apoplexy remains unclear, and it is unknown whether it involves primary hemorrhage or hemorrhagic infarctation. The size of the adenoma appears to be the greatest risk factor; patients with macroadenomas (tumors > 1 cm) are more likely to develop this complication than patients with microadenomas (tumors < 1 cm) (2-4). The reason for this difference remains unknown. Morphologically, the vessels of a pituitary adenoma display characteristics of incomplete maturation and poor fenestration, and their basal membranes are often ruptured (5). These structural abnormalities can contribute to susceptibility to spontaneous hemorrhage, and therefore represent a potential mechanism for the occurrence of apoplexy (1).

In 60% to 80% of cases, pituitary tumor apoplexy has occurred spontaneously in an asymptomatic pa-
Conservative management of pituitary apoplexy

CASE REPORTS

Case 1

A 38-year-old male patient was admitted to the Clinical Hospital of Botucatu Medical School because of a sudden intense headache in the frontal and retroocular regions, accompanied by nausea and vomiting, and a 3-week history of “blurred vision”. Physical examination showed bitemporal hemianopsia and paralysis of the left sixth cranial nerve, but was otherwise unremarkable. His past medical history was also unremarkable.

Cranial computed tomography revealed a pituitary tumor with compression of adjacent structures. Pituitary MRI demonstrated a solid expansive process (3.0 x 2.9 cm) with hypersignal on T1-weighted images, supra- and para-sellar extension, and optic chiasm compression, findings compatible with pituitary macroadenoma and apoplexy (Figure 1). Laboratory test results showed central hypocortisolism (basal cortisol 1.21 μg/dL, reference value [RV]: 5-25 μg/dL), hypogonadism (total testosterone < 20 ng/dL, RV: 181-758 ng/dL; luteinizing hormone [LH] 0.28 mUI/mL, RV: 0.8-7.6 mUI/mL; follicle stimulating hormone [FSH]: 0.67 mUI/mL, RV: 0.7-11.1 mUI/mL), and central hypothyroidism (thyroid stimulating hormone [TSH] 0.05 μIU/mL, RV: 0.4-4.0 μIU/mL; free T4: 0.51 ng/dL, RV: 0.8-1.9 ng/dL), without hypersecretion of other hormones (growth hormone [GH] 0.14 ng/dL, RV: 0-5 ng/dL; insulin-like growth factor 1 – IGF-1 – and prolactin in normal ranges).

The patient was treated conservatively with intravenous hydrocortisone, hydration, and analgesics. He was hospitalized for 20 days and remained clinically stable, with no progression of neurological deficits. After 3 months, the patient’s visual deficits and central hypogonadism were resolved. His visual fields were normal, total testosterone was 479 ng/dL, and repetition of the MRI demonstrated normal pituitary gland (1.0 x 0.9 x 0.8 cm; Figure 2). He was maintained on levothyroxine treatment, but corticosteroid replacement therapy was discontinued to see if the deficit was resolved. Hormone replacement restarted few months later, when the patient presented symptoms of adrenocortical deficiency and low basal cortisol level.

Two years later, the patient still needs thyroid and corticosteroid replacement therapy, but his pituitary MRIs have been normal, and he remains free of headaches and visual deficits. His gonadotrophic axis also remains normal (total testosterone: 521 ng/dL).

Here, we describe two patients with clinically non-functioning pituitary macroadenomas who developed pituitary tumor apoplexy that was treated conservatively.
Conservative management of pituitary apoplexy

Case 2
A 75-year-old male patient was admitted to the Clinical Hospital of Botucatu Medical School with a 3-day history of sudden-onset frontal and right parietal headache. He also had a 6-month history of protrusion of his right eye, reduced libido, and excessive somnolence, and an 1-year history of arterial hypertension, controlled by medication. Physical examination revealed proptosis and blindness of the right eye, and no other abnormal findings.

MRI showed a pituitary tumor (2.3 x 1.8 x 1.9 cm) with supra-sellar expansion, compression of the optic chiasm, and hypersignal on T1-weighted images, findings compatible with pituitary macroadenoma apoplexy (Figure 3). Laboratory test results indicated central hypocortisolism (basal cortisol 1.1 μg/dL, RV: 5-25 μg/dL), hypogonadism (total testosterone < 20 ng/dL, RV: 181-758 ng/dL; LH 1.29 mUI/mL, RV: 0.8-7.6 mUI/mL; FSH 3.58 mUI/mL, RV: 0.7-11.1 mUI/mL), and central hypothyroidism (TSH 0.31 mIU/mL, RV: 0.4-4.0 mIU/mL; free T4 0.7 ng/dL, RV: 0.8-1.9 ng/dL), without hypersecretion of other hormones (GH 0.4 ng/dL, RV: 0.5 ng/dL; IGF1 and prolactin in normal ranges).

The patient was treated conservatively with intravenous hydrocortisone, hydration, and analgesia, and levothyroxine supplementation began. He had no progression of neurological deficits and elective surgery was delayed. Two months later, he presented complete resolution of both his right eye proptosis and central hypogonadism, but still had amaurosis of the right eye. MRI showed regression of the adenoma (1.7 x 1.3 x 1.1 cm) and it no longer compressed the optic chiasm. Conservative treatment, consisting of levothyroxine and corticosteroid replacement therapy, continued. Ten months after admission, MRI showed further regression of the adenoma (0.9 x 0.8 x 0.9 cm; Figure 4).
Two years later, the patient still needs thyroid and corticosteroid replacement therapy, but his hypogonadism remains in remission (free T4 1.1 ng/dL, total testosterone 311 ng/dL). He is still blind in the right eye. Follow-up pituitary MRI findings are compatible with empty sella.

**DISCUSSION**

Morbidity and mortality of patients with pituitary tumor apoplexy have declined over the past 6 decades. Factors that may have contributed to this include improvement in diagnostic accuracy, more sophisticated therapeutic support, use of glucocorticoids, and refinement of surgical and postoperative techniques (1). Untreated patients may continue to have high morbidity and mortality; before the use of glucocorticoids, mortality was approximately 50% (1).

Patients with signs and symptoms of pituitary tumor apoplexy require thorough clinical evaluation and continuous monitoring to care for their neurological, ophthalmological, and endocrine dysfunctions. After hemodynamic stabilization and glucocorticoid replacement, it is important to choose the best treatment option for the improvement or stabilization of the patient’s neuro-ophthalmological deficits. Immediate surgical intervention for apoplexy remains controversial. Several reports showed that spontaneous neurological recovery is possible, and some authors reported that patients treated conservatively had neurological and neuro-ophthalmological recovery rates similar to those of patients treated surgically (9). Other more recent retrospective studies have also provided evidence that nonsurgical treatment of patients with pituitary tumor apoplexy may be safe for patients who do not present visual deficits or show early evidence of recuperation from this condition (10,11). On the other hand, results of trans-sphenoid decompression immediately after stabilization of the patient have been very good, and recovery of neurological and pituitary function occurs within a period of several hours to days.

The two patients reported here achieved tumor remission with conservative treatment. One recovered completely from his visual deficit, and both showed normalization of at least one of the compromised pituitary hormone axes.

New studies with methodologies appropriate for clinical decision-making are needed to determine the optimal time for surgical intervention in the treatment of pituitary tumor apoplexy. Until then, the decision must be individualized, using a multidisciplinary approach that encompasses all aspects of the patient’s clinical condition.

Disclosure: no potential conflict of interest relevant to this article was reported.

**REFERENCES**